19648-66-9Relevant academic research and scientific papers
BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS
-
Page/Page column 43, (2011/04/26)
The invention is concerned with novel bicyclic compounds of formula (I), wherein A, L, E, F, G, R1, R2, R3, R4, R5, R6, R7, V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compound
NOVEL BICYCLIC COMPOUNDS
-
Page/Page column 18, (2011/04/24)
The invention is concerned with novel bicyclic compounds of formula (I), wherein A, L, E, F, G, R1, R2, R3, R4, R5, R6, R7, V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
Terephthalamide derivatives as mimetics of helical peptides: Disruption of the Bcl-xL/Bak interaction
Yin, Hang,Lee, Gui-In,Sedey, Kristine A.,Rodriguez, Johanna M.,Wang, Hong-Gang,Sebti, Said M.,Hamilton, Andrew D.
, p. 5463 - 5468 (2007/10/03)
A series of Bcl-xL/Bak antagonists, based on a terephthalamide scaffold, was designed to mimic the α-helical region of the Bak peptide. These molecules showed favorable in vitro activities in disrupting the Bcl-xL/Bak BH3 domain comp
